Improved prognosis for elderly patients with metastatic renal cell carcinoma in the era of targeted therapy.

The present study investigated the outcomes of targeted therapy for elderly patients with metastatic renal cell carcinoma (mRCC). A total of 277 patients with mRCC who were treated with tyrosine kinase inhibitor as a first-line therapy from January 2008 to May 2018 were retrospectively investigated by reviewing clinicopathological data. Patients 75 years or older were classified into the older-aged group (n=55) while all others were classified into the younger-aged group (n=222). The preoperative clinicopathological characteristics and the overall survival (OS) rate for these two groups were subsequently compared. The median age in the older- and younger-aged groups was 78 and 63 years (P<0.0001), respectively. A total of 7, 42 and 6 cases in the older-aged group and 46, 118 and 58 cases in the younger-aged group were classified into favorable, intermediate, and poor risk groups, respectively. The rate of patients with cardiovascular diseases (29.1%) and malignant diseases other than RCC (20.0%) was significantly higher in the older-aged group compared with the younger-aged group (6.8%; P<0.0001 and 7.2%; P=0.0042, respectively). There was a significant improvement in the OS rate for patients beginning targeted therapy after 2011 compared with those starting therapy prior to 2010. The 50% OS rate in patients starting targeted therapy before 2010 and after 2011 was, respectively, 17.1 and 38.6 months for the older-aged group (P=0.0066), while there was no significant difference for the younger-aged group (P=0.1441; 50% OS; 35.9 vs. 30.5 months). The results of the present study indicated that the prognosis for older patients has improved since the introduction of targeted therapy.

Molecular and clinical oncology. 2020 Mar 24 [Epub]

Jun Teishima, Daiki Murata, Shogo Inoue, Tetsutaro Hayashi, Koji Mita, Yasuhisa Hasegawa, Masao Kato, Mitsuru Kajiwara, Masanobu Shigeta, Satoshi Maruyama, Hiroyuki Moriyama, Seiji Fujiwara, Akio Matsubara

Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan., Department of Urology, Hiroshima-City Asa Citizens Hospital, Hiroshima 731-0293, Japan., Department of Urology, Fukuyama Medical Center, Fukuyama, Hiroshima 720-8520, Japan., Department of Urology, Hiroshima General Hospital, Hatsukaichi, Hiroshima 738-8503, Japan., Department of Urology, Hiroshima Prefectural Hospital, Hiroshima 734-8530, Japan., Department of Urology, Kure Medical Center and Chugoku Cancer Center, Kure, Hiroshima 737-0023, Japan., Department of Urology, Miyoshi Central Hospital, Miyoshi, Tokushima 728-8502, Japan., Department of Urology, Onomichi General Hospital, Onomichi, Hiroshima 722-8508, Japan., Department of Urology, Higashi-Hiroshima Medical Center, Higashi-Hiroshima, Hiroshima 739-0041, Japan.